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C A N C E R
The clonal evolution of metastatic colorectal cancer
Ha X. Dang1,2,3, Bradley A. Krasnick3,4,5, Brian S. White6, Julie G. Grossman3,4,5, Matthew S. Strand3,4,5, 
Jin Zhang7, Christopher R. Cabanski8, Christopher A. Miller1,2, Robert S. Fulton2, 
S. Peter Goedegebuure3,4,5, Catrina C. Fronick2, Malachi Griffith1,2,9, David E. Larson2, Brian D. Goetz3, 
Jason R. Walker2, William G. Hawkins3,4,5, Steven M. Strasberg3,4,5, David C. Linehan10, Kian H. Lim1, 
A. Craig Lockhart11, Elaine R. Mardis12,13, Richard K. Wilson12,13, Timothy J. Ley1,2,3, 
Christopher A. Maher1,2,3,14*, Ryan C. Fields3,4,5*†
Tumor heterogeneity and evolution drive treatment resistance in metastatic colorectal cancer (mCRC). Patient- 
derived xenografts (PDXs) can model mCRC biology; however, their ability to accurately mimic human tumor 
heterogeneity is unclear. Current genomic studies in mCRC have limited scope and lack matched PDXs. Therefore, 
the landscape of tumor heterogeneity and its impact on the evolution of metastasis and PDXs remain undefined. 
We performed whole-genome, deep exome, and targeted validation sequencing of multiple primary regions, 
matched distant metastases, and PDXs from 11 patients with mCRC. We observed intricate clonal heterogeneity 
and evolution affecting metastasis dissemination and PDX clonal selection. Metastasis formation followed both 
monoclonal and polyclonal seeding models. In four cases, metastasis-seeding clones were not identified in any 
primary region, consistent with a metastasis-seeding-metastasis model. PDXs underrepresented the subclonal 
heterogeneity of parental tumors. These suggest that single sample tumor sequencing and current PDX models 
may be insufficient to guide precision medicine.
INTRODUCTION
Colorectal cancer (CRC) is the most common gastrointestinal 
malignancy and is a leading cause of cancer-related death. Since the 
initial description of the “adenoma-carcinoma” initiation of primary 
CRC (1), the genomic landscape of primary CRC has been detailed 
by large-scale sequencing studies (2).
The genomic characterization of metastatic CRC (mCRC) includes 
studies using exome or targeted sequencing of cancer-related genes 
with limited breadth and depth of coverage, some of which directly 
compare metastases to their matched primary tumors (3–8). These 
studies have allowed us to begin to understand the clonal progres-
sion and evolution of metastases; however, notable limitations 
exist. First, exome- and gene panel–targeted sequencing have limited 
breadth of coverage that primarily targets the coding regions that 
represent ~2% of the genome, and therefore, they are unable to 
identify the majority of passenger mutations, which are mostly in 
the noncoding genome. However, whole-genome sequencing allows 
for the detection of many more mutations, which improves cancer 
cellular prevalence estimates. Second, most studies only evaluated 
one biopsy per tumor, thus largely underestimated the intratumor 
heterogeneity, particularly in the primary tumors. To be able to 
understand the evolution of metastases, comprehensively evaluating 
the primary tumor is essential, as metastasis-seeding clones could 
be present at low frequency in the primary tumors and not captured 
in single region sequencing. Because of these limitations in current 
studies, critical questions on mCRC metastatic evolution have not 
been comprehensively addressed: Do metastases arise from single or 
multiple cells? Do metastases occur after multiple clonal expansions 
in the primary? Do metastases seed other metastases?
The practice of using human tumors grown in immunosuppressed 
mice [referred to as patient-derived xenografts (PDXs)] has been widely 
used to model cancer biology, predict treatment response, and de-
lineate mechanisms of therapy resistance (https://pdmr.cancer.gov/) 
(9). However, it is not clear how accurately PDX models capture the 
genomic heterogeneity observed in human tumors, creating doubt 
regarding their utility for precision medicine applications (10–12). 
There exists no study in mCRC that evaluated the clonal heterogeneity 
and evolution of PDXs in conjunction with their matched primary 
and metastatic tumors from the same patients.
We prospectively collected matched normal, primary, and metastatic 
tumor tissues from patients with mCRC and developed PDXs from this 
cohort, allowing us to deeply explore the landscape of tumor hetero-
geneity and clonal evolution. Here, we report on the comprehensive 
genomic profiling of 102 samples (11 matched normal and 91 unique 
patient and PDX tumor samples) from 11 patients with mCRC. These 
results describe complex intratumor heterogeneity and its impact 
on the formation and evolution of metastasis and the relationship of 
PDXs to patient tumors, which have important clinical implications.
RESULTS
Somatic mutations in mCRC
We sequenced 91 unique tumor specimens (58 multiregion primary 
tumor samples, 24 metastatic samples, and 9 PDX samples) and 
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11 matched normal samples from 11 patients (CRC1 to CRC11) with 
mCRC (Fig. 1 and table S1). All patients were microsatellite stable. 
Eight patients received chemotherapy before primary or metastatic 
tumor resection (Fig. 1). The initially resected primary tumor region 
and all metastases were sequenced using both whole-genome and 
exome sequencing, and PDXs were sequenced using exome sequencing 
for the discovery of somatic mutations. Subsequently, all samples, 
including 47 remaining multiregion primary samples, were then 
subjected to a targeted validation sequencing of 152 cancer genes and 
>100,000 somatic mutations chosen in the discovery phase (Fig. 1).
Analysis of whole-genome, exome, and targeted validation sequenc-
ing data identified ~11,000 somatic mutations per patient, including 
single nucleotide variants (SNVs) and indels (fig. S1). The most 
frequently mutated genes were genes known in CRC including 
APC, TP53, KRAS, PIK3CA, TCF7L2, SMAD3, and SMAD4 (1, 2). 
Frequent copy number gain was observed in IRS2, EGFR, and MYC, 
while frequent copy number loss was observed in TP53, SMAD4, 
TCF4, and NRAS. Direct comparison of mutational profiles of 
matched primary and metastatic samples revealed very few cancer- 
related genes mutated in the metastasis that were not seen in any 
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Patient Age Sex Stage* Prim. site Met. site Diag.& Chemo.$ Normal Prim. regions Metastases PDXs
CRC1 41 M 4/T3N1cM1b Colon Liver S Yes 1 3 3 3
CRC2 71 M 4/T3N2aM1a Colon Liver S Yes# 1 14 2 1
CRC3 57 M 4/T3N2bM1a Colon Liver S Yes# 1 5 2 1
CRC4 63 M 2a/T3N0M0 Colon Liver M No 1 5 1 0
CRC5 40 M 4/T4bN1bM1a Rectum Liver S Yes 1 10 1 1
CRC6 48 M 3b/T3N1bM1b Colon Liver S Yes# 1 6 2 1
CRC7 61 M 3a/T2N1bM0 Rectum Liver M Yes# 1 3 3 0
CRC8 67 F 4/T3bN1M1 Colon Liver S No 1 2 3 0
CRC9 44 M 4/T2N2aM1b Colon Liver/abd. wall/brain S Yes# 1 2 3 0
CRC10 59 M 4/T3N1aM1a Colon Liver S No 1 7 3 2
CRC11 72 F 4/T3N1M1a Rectosigmoid Liver S Yes 1 1 1 0
Subtotal 11 58 24 9* AJCC 8th Edition.
& S – synchronous: metastasis present at diagnosis; M – metachronous: metastasis discovered within 6 months after initial diagnosis.
$ Chemotherapy agents and duration are in Fig. 3 and figs. S2 to S10.
# Primary tumor was resected before chemotherapy.
Fig. 1. Overview of patient cohort, samples, and study design. (A) Summary of the clinical data. (B) Locations of the primary tumors and distant metastasis sites for all 
11 patients. Sample names are prefixed by a letter representing the site of tumor (P, primary; L, liver metastasis; A, abdominal wall metastasis; and B, brain metastasis). 
Tumor diameters are in the gray boxes. The number of red dots inside red dashed circles indicates the total primary regions for the corresponding primary tumors. Several 
primary and metastasis samples were implanted into immunodeficient mice yielding PDX tumors (named with suffix letter X with a green dotted arrow linked to the 
parental patient sample). (C) Sequencing and clonal evolution analysis.
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of the primary regions evaluated in the same patient (fig. S1 and 
Fig. 2).
To characterize metastatic progression, we reconstructed the 
clonal evolution of the tumors within individual patients and found 
that metastasis was often established after the accumulation of a 
large number of mutations and acquisition of many driver events 
(Fig. 2 and data S1), consistent with previous studies (3, 7). On 
average, the numbers of clonal marker variants that we were able to 
assign were ~1507 (~58 coding) for the founding clones and ~155 
(~7.3 coding) for the subclones (data S3). Genes commonly mutated 
before metastasis establishment included APC, TP53, KRAS, PIK3CA, 
TCF7L2, and SMAD4. To further delineate potential metastasis drivers, 
we traced subclones leading to metastasis (i.e., those detected in the 
primary tumor that seeded metastasis). We found several mutations 
as clonal marker variants of clones that metastasized, including 
those targeting PTEN, PIK3CG, ROBO1, DMD, CDH11, and LRP1B 
(Fig. 2; pink mutations).
Intra- and intertumor heterogeneity is substantial and is 
reflected in metastatic progression
An understanding of the intra- and intertumor heterogeneity of mCRC 
and how it is reflected in the evolution and establishment of distant 
metastases may have implications in the response to treatment and 
subsequent development of resistance. We sampled all available 
metastatic sites and profiled all areas of the primary tumors where 
high-quality unique tissue cores could be extracted, yielding as many 
as 14 regions from a single primary tumor (Fig. 1). In general, we 
sequenced higher numbers of primary regions from bigger tumors 
(Pearson correlation, ~0.8; Fig. 1). We observed substantial intratumor 
heterogeneity with metastatic progression. All unique specimens 
carried only a subset (~10 to 70%; mean, 25%) of total clones identified 
in all samples from a given patient (Fig. 3A). Primary and metastasis- 
specific subclones were found in all patients (Fig. 2). Notably, the 
metastasis-founding subclones were not detected in any primary 
regions we studied in four cases (CRC3, fig. S2; CRC4, fig. S3; CRC8 
clone 5, fig. S4; and CRC9 clone 4, fig. S5) and were detected in only 
a subset of primary regions in six cases (CRC2, Fig. 3; CRC5, fig. S6; 
CRC6, fig. S7; CRC7, fig. S8; CRC9 clone 5, fig. S5; and CRC1, fig. S9). 
In the case with the highest number of primary regions (CRC2), two 
metastasis-seeding subclones were found with low cellular fractions 
in fewer than 3 of the 14 primary regions (Fig. 3). Subclone 4 (salmon 
color) seeding metastasis L1 was found in only one primary region 
(P9 at 5%). Subclone 10 (brown color) seeding metastasis L2 was 
found in only two primary regions (P3 at 3.5% and P8 at 3%; Fig. 3). 
While mutations in APC, TP53, KRAS, PIK3CA, TCF7L2, and SMAD4 
were often clonal, mutations in SMAD3, CDH11, CSMD1, EP300, 
and ROBO1 were usually subclonal (figs. S1 and S2).
The clonal evolution of individual patients highlights heteroge-
neous subclonal mutations found in genes likely contributing to 
metastasis or treatment resistance: KRAS (13, 14) (CRC2), PTEN 
(15) (CRC6), and PIK3CG (16) (CRC7). Most notably, a subclonal 
KRAS Q22K mutation was present in only 3 of 14 primary regions 
from CRC2 and was not detected by clinical genomic testing of the 
standard-of-care clinical biopsy (Fig. 3). The KRAS Q22K mutation 
is known to activate KRAS and increase RAS–GTP (guanosine tri-
phosphate) levels (17), a mechanism of resistance to EGFR inhibitors 
(13). This suggests that rare subclones could carry clinically relevant 
mutations that may only be detected by extensive, multiregion 
genomic profiling. In addition, a PTEN F56L mutation in patient 
CRC6 was a marker of the founding clone of the PDX derived from 
a metastasis, but it was subclonal in the primary tumor. It may 
therefore be a driver of the metastatic subclones found in the primary 
tumor (fig. S7) (15).
While most chromosomal aberrations were early clonal events 
(data S2), we also found subclonal copy number alterations includ-
ing amplification of EGFR (CRC9 and CRC10) and WNT2 (CRC7 
and CRC9) and deletion of FBXW7 (CRC1), APC, PTEN, TCF7L2, 
TET1 (CRC8), and NRAS (CRC9) (fig. S1). Notably, we found that 
patient CRC8 had large deletions involving chromosome 5 (carrying 
APC) and chromosome 10 (carrying PTEN and TCF7L2) that were 
among the subclonal events that occurred independent of the sub-
clone that seeded first liver metastasis L1 (fig. S4B). The mutant 
alleles of APC and TCF7L2 were lost, and the subclone carrying the 
losses of APC, PTEN, and TCF7L2 seeded two liver metastases L2 
and L3. This suggests that metastasis can develop from cells carrying 
monoallelic inactivation of APC contrasting with biallelic inactiva-
tion of APC in other APC-positive patients (fig. S1). Similar to the 
PTEN mutation in CRC6, loss of PTEN in CRC8 may have contrib-
uted to clonal expansion and metastasis.
Distant metastases can arise via polyclonal seeding
Single-cell seeding has classically been viewed as the primary model 
of metastasis dissemination in cancer (18). However, there is grow-
ing evidence that metastasis seeding may involve or require the 
cooperation of multiple cells that either represent a single clone 
(monoclonal seeding) or multiple distinct clones (polyclonal seeding) 
(19, 20). Our data provide the ability to find rare metastasis-seeding 
subclones present in primary tumors. We identified two cases 
(CRC5 and CRC7) whose metastases were seeded by multiple 
distinct clones from the primary tumor (Fig. 4 and figs. S6 and S8). 
We observed at least one subclone with marker variants that were 
present at subclonal levels in both the primary and metastasis. This 
supports polyclonal metastasis seeding by the subclones and one of 
their ancestor clones that was also found to be present in both the 
primary and metastasis. In CRC5, the founding clone (1) and two 
subclones (2 and 3) in the primary tumor were found to seed the 
liver metastasis (fig. S6). The metastasis-seeding subclones were not 
present in the first primary region (P1) but were present in all the 
subsequently studied primary regions (fig. S6). In CRC7, at least 
three clones, including the founding clone (1) and two subclones 
(2 and 4), were identified in metastases. Those clones were involved 
in the establishment of three liver metastases: two were seeded by 
multiple clones/cells, and one was seeded by a single clone/cell (fig. S8). 
In this case, the metastasis-seeding clones were present in only a 
subset of the primary regions (fig. S8). We also observed two cases 
where the metastasis-seeding clones were present at the subclonal levels 
only in the metastatic samples (Fig. 4), suggesting polyclonal metastasis 
seeding from one metastasis to another metastasis. In summary, 
metastatic biology and progression have been thought to follow a 
single-cell seeding mechanism (a monoclonal model). This model 
was supported in seven of our cases. However, polyclonal metastasis 
seeding was detected in four cases (CRC5, CRC7, CRC8, and CRC10).
Model of metastasis-seeding-metastasis
Recent progress in understanding metastatic progression has high-
lighted several mechanisms that allow a metastasis-seeding clone to 
leave the primary tumor (“seed”) and grow in a distant organ where 
it finds an appropriate “soil” (21). However, it is not clear whether 
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the seed or its evolved progeny are able to leave the soil again, allow-
ing metastasis to seed another metastasis via hematogenous spread 
(22). Our clonal evolution models revealed four cases (CRC3, 
CRC8, CRC9, and CRC10) where the clonal marker variants of the 
metastasis-seeding clones were not detected in any of the primary 
regions (Fig. 5 and figs. S4 and S10) but were observed in another 
metastasis. This observation raises a possibility that those mutations 
arose in the metastasis itself, consistent with a metastasis-seeding- 
metastasis model.
In CRC8, clonal marker variants of subclone 3 were present in 
two distinct metastatic sites in the right lobe of the liver (L2 and L3, 
respectively). None of the three primary regions contained mutations 
found in the metastasis-shared subclone, suggesting the shared 
clone and its parent were involved in the seeding between the two 
liver metastases (Fig. 5 and fig. S4). In CRC10, none of the seven 
primary regions captured either of the two metastasis-seeding sub-
clones between liver metastases L1 and L2 and between L1 and L3 
(Fig. 5 and fig. S10). In CRC9, a subclone shared between the 
abdominal wall metastasis and brain metastasis was not detected 
elsewhere (Fig. 5B and fig. S5). The marker variants of this clone 
were found to be present at similar levels in the brain metastasis, 
indicating a monoclonal metastasis-seeding-metastasis mechanism. 
In CRC3, two liver metastases L1 and L2 shared variants (clone 3, 
green color) that were not detected in all primary regions, also 
supporting a monoclonal metastasis-seeding-metastasis model 
(fig. S2).
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PDX models underestimate the heterogeneity of  
parental tumors
Our comprehensive genomic profiling and clonal evolution models 
allowed for extensive characterization of PDXs and comparison to 
their parental (patient) tumors. Furthermore, our PDX generation 
from subcutaneous injection of single-cell suspensions is expected 
to reduce geographic selection bias. We observed substantial sub-
clonal skewing in xenografts compared with their matched parental 
samples (Fig. 6). In four of nine xenografts, the dominant parental 
tumor clones were underrepresented, while minor parental subclones 
Distinct primary regions Distinct metastases PDX
B
C
D
G
APC_p.R876*
AXL_p.A79T
CSMD1_p.T2897M
CSMD3_p.D1356N
LRP1B_p.D1614N
PIK3CA_e2−2
TCF7L2_p.V368I
TP53_p.C238Y
ROBO1_p.K766N
PTPRS_p.A907V
DMD_e63−9
KRAS_p.Q22K
LRP1B_p.A2599E
CSF1R_p.G589R
C
lu
st
er
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
2 2 5 2 4 2 3 4 6 3 1 3 4 4 2 3 1
E
KRAS KRASKRAS
L1L2
P
L2X
6
8
9
10
14
16
17
*P14,*P13,P9*P5,*P4,*P2
P13,*P7,P5
*P14,*P10,*P8,*P3
P8,P3
*L2
L2,*L2XL2
LRP1B_p.A2599E
CSF1R_p.G589R
2 4
5
15
*P9,*P
13,*P
12,*P
14
P9
P9
*L1
L1
ROB
O1_p
.K76
6N
DMD
_e63
−9
PTPRS_p.A907V
P12,P9,
*P8,*P6,*P3
3
7
12
13
18
11
P8
,P
6,
P3
*P
14
,*P
13
,P
9,
*P
5,
P3
*P
12
,*P
11
,*P
10
*P
7,
P5
,*P
4,
*P
2
*P
1,
P1
0,
P7
P1
KRAS_p.Q22K
1
APC_p.R876*
AXL_p.A79T
CSMD1_p.T2897M
CSMD3_p.D1356N
LRP1B_p.D1614N
PIK3CA_e2−2
TCF7L2_p.V368I
TP53_p.C238Y
APC_loh
TP53_loh
SMAD4_del
MYC_amp
IRS2_amp
WNT2_amp
EGFR_amp
NCOR1_loh
TCF4_del
CDC27_loh
CDK12_loh
A
P resected
L1 resected
L2 resected
L2X engraftment
L2X resected
FOLFOX
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
ROBO1 DMD
KRAS
L1
P
L2 L2X
Time
0
25
50
75
100
Pe
rc
en
t o
f t
ot
al
 c
lo
ne
s
Primary
Metastasis
PDX
CRC1 9CRC 01CRC7CRC 8CRCCRC64CRC 5CRCCRC3CRC2
F
IRS2
WNT2
NCOR1
SMAD4
MYC
EGFR
CDC27
CDK12
TCF4
Mutation
Mutation & copy number
Copy number
Gene alteration type
APC
TP53
TCF7L2
AXL
CSMD1/3
PIK3CA
Cancer initiated
Fig. 3. CRC has substantial heterogeneity reflected in metastatic progression and establishment of PDXs. (A) Percentage of total patient cancer clones detected in 
individual samples. (B to G) Clonal heterogeneity and evolution in patient CRC2. (B) Clustering of variants displaying purity-corrected cancer cellular fraction (CCF) across 
14 primary regions, 2 metastases, and a PDX. Black bars, mean CCFs; red dots, nonsilent mutations in cancer genes (details on the far right). (C) Fishplot of clonal evolution 
and (D) clonal admixture of individual samples. (E) Clonal evolution tree with branch length scaled by the square root of the number of clonal marker variants. (F) Fishplot 
of the clonal evolution across all samples (time not to scale; sample acquisitions at the right end). Treatments are presented at the bottom. Primary tumor is presented as 
a combination of all primary regions. Arrows indicate metastasis seeding. Cancer genes, whose somatic alterations are clonal markers of a clone, are indicated with arrows 
pointing to the tips of the fishplot corresponding to the clone. (G) Anatomic representation of tumor location and metastatic progression. Arrows represent seeding 
clones between samples/sites. Dashed arrows represent clones regressed in PDX. Colors are matched throughout panels (B to G).
 on S
eptem
ber 2, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Dang et al., Sci. Adv. 2020; 6 : eaay9691     10 June 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 11
became dominant (CRC2, CRC10/P1X, and CRC1/P1X,L2X). Only 
two xenografts contained all of the subclones found in the parental 
tumor, but in these cases, the parental sample contained a small 
number of subclones (CRC3 L2/1 clone and CRC10 L2/2 clones). 
Six other xenografts lost between 20 and 67% of clones compared 
with their parental tumors (Fig. 6).
Mutations in well-characterized CRC genes (such as APC, TP53, 
and TCF7L2) were among the initiating events for several tumors 
and were concordant between the parental sample and PDX tumors, 
as expected. However, we also found subclonal mutations that were 
underrepresented in the PDX compared with the parental tumor in 
ROBO1 (CRC10, fig. S10), SMAD3, and KMT2C (CRC1, fig. S9). 
Additional comparison of PDX tumors, multiregion primary, and 
metastasis tumors revealed subclonal mutations with implications 
for treatment that were present in nonparental patient tumors but 
absent in the PDX. For example, in patient CRC2, a subclonal KRAS 
Q22K mutation present in only 3 of 14 primary regions was not re-
capitulated in the PDX (Figs. 3 and 6). Together, these observations 
demonstrate that the clonal heterogeneity of CRC tumors is not 
accurately represented by PDX models.
DISCUSSION
We used comprehensive genome sequencing to study clonal evolution 
in mCRC and defined the relationship between PDXs and patient 
tumors. Our reconstruction of the clonal evolution of patients with 
mCRC highlights complex intra- and intertumor heterogeneity re-
flected in metastasis dissemination and xenograft clonal selection. 
This may have direct clinical implications, as the failure of cancer 
therapies is clearly related to tumor heterogeneity and the constant, 
adaptive evolution of human tumors in the context of treatment 
response and resistance.
Treatment decisions in clinical oncology are largely based on the 
principle that metastases are seeded by cells from the tumor of origin 
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(23). Metastatic biology and progression have also been thought to 
follow a single-cell seeding mechanism (a monoclonal model). This 
model was supported in seven cases. However, polyclonal metastasis 
seeding was detected in four cases (CRC5, CRC7, CRC8, and CRC10). 
This result is consistent with the earlier analyses using exome data 
(5, 24). Earlier study also found distinct origins between lymph 
node and distant metastases in primary tumors (4), supporting our 
model of primary seeding metastasis. Moreover, our whole-genome 
data allowed us to reconstruct more detailed metastasis seeding 
models that involved subclones established late after multiple clonal 
expansions, consistent with an earlier smaller study using single-cell 
sequencing (7). Clearly, metastasis is a complex process that may 
require the cooperation of multiple cells from different subclones or 
occur in multiple rounds of seeding that involve distinct clones. These 
findings suggest the need for new approaches to target the interac-
tions of multiple cells and/or clones to inhibit the establishment and 
progression of metastases.
Our multiregion and whole-genome analysis allowed us to ex-
tensively assess the intratumor heterogeneity of the primary tumor 
and how it is reflected in metastasis. Compared with earlier exome 
or targeted sequencing studies (4, 6, 25), our analysis revealed sub-
stantial intratumor heterogeneity in the primary tumor affecting the 
metastasis dissemination. We frequently observed that metastases 
were seeded by rare subclones from the primary tumor. Potential 
metastatic clones do not necessarily represent the most abundant 
subpopulations in the primary tumor; instead, some metastasis-prone 
subclones may have a survival advantage in the bloodstream or may have 
a growth advantage in specific distant organs. Notably, metastasis- 
seeding clones are often seen in only a small subset of primary re-
gions as a result of spatial heterogeneity in the primary tumor. This 
poses a challenge to design effective personalized therapies using a 
single or limited number of biopsies collected at a tumor site. Circulat-
ing tumor cells and/or DNA could potentially complement tumor 
biopsies by providing genomic signatures of subclones traveling be-
tween distant tumors (26).
As the first study to assay xenograft tumors together with 
matched primary regions and distant metastases, we showed that 
intratumor heterogeneity coupled with clonal selection in PDX 
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models could result in a limited understanding of a patient’s entire 
cancer using single biopsy and xeno-engraftment experiments. This 
is a reflection of the inherent heterogeneity in developing PDXs and 
other model systems based on a small biopsy or operative specimen 
used for research taken from a larger tumor that results in a model 
that does not contain all of the cellular components of a complex 
tumor. This issue is even more complex due to the patient tumor 
microenvironment, which is increasingly recognized to influence 
clinical outcomes (27) but not modeled in PDXs. Furthermore, distinct 
tumor clones could demonstrate various survival capabilities in novel 
microenvironments when introduced to mouse models. Higher- 
resolution single-cell analyses of tumors corroborate this research 
as substantial diversity, and differential treatment responses were 
observed in patient-derived organoids (PDOs) developed from single 
CRC cells from one biopsy (12). Another study found that PDOs 
recapitulated the characteristics of the parental tumors from which 
they were derived, including responsiveness to a panel of drugs (11). 
While only a subset of clones is often represented in PDXs and PDOs, 
these models could still mimic treatment response of the parental 
tumor and may cause these different observations between studies. 
However, mutations in targetable or treatment-resistant markers 
(such as KRAS and PTEN) could be easily missed in a single biopsy, 
leading to missed opportunities for timely and effective therapy. 
Furthermore, with the success of immunotherapies in the treatment 
of solid tumors (28), ensuring that tumor biopsies recapitulate the 
complete clonal and mutational spectrum of a tumor (including all 
potential neoantigens) may prove to be very important.
Last, our analysis suggests that metastases may seed other metastases. 
Although there is a possibility that the seeding clones found in multiple 
metastases were not detectable in the primary due to unsequenced 
regions (those used for diagnostics or having low-quality material) 
or low clonal frequency, we have made an attempt to exhaust the 
primary tumors by sequencing all available tumor regions with high- 
quality DNA. Our results, although remaining to be validated, are 
indeed consistent with previous studies in circulating tumor cells. 
Circulating tumor cells can be seen in both patients with localized 
and metastatic diseases and are often more abundant in metastatic 
patients (29). Mutations specific to metastasis can also be detected 
in the blood (30). Together, this suggests that tumor cells are released 
into the blood from both primary and metastatic sites and, therefore, 
are capable of traveling to distant organs. The ability of metastases 
to seed other metastases has implications for clinical decision-making 
in patients with metastatic cancer, where directed therapy to a site 
of metastasis could affect subsequent progression.
These data provide insights into several aspects of CRC, in-
cluding treatment response, the development of resistance, 
metastatic progression, and preclinical cancer modeling. The char-
acterization of the complex clonal evolution from primary tumor to 
metastases may have direct implications for the treatment of 
patients with CRC.
MATERIALS AND METHODS
Patient cohort and sample acquisition
We evaluated matched normal, primary, and metastasis samples from 
11 patients (CRC1 to CRC11) with mCRC undergoing treatment at 
the Alvin J. Siteman Cancer Center at the Washington University 
School of Medicine in St. Louis, MO, USA. This included a total of 
102 samples including 91 unique tumor specimens (58 multiregion 
primary tumor samples, 24 metastatic samples, and 9 PDX samples) 
and 11 matched normal samples (10 from the blood and 1 from 
uninvolved colon) (Fig. 1 and table S1). Our protocol allowed the 
retrieval and pathological evaluation of the archived primary tumors 
to select for regions with high tumor content and high isolated DNA 
quality for multiregion sequencing (see the Supplementary Methods). 
This yielded various numbers of primary regions per patient depend-
ing on tissue quality (Fig. 1). All patients provided informed consent 
under an institutional review board–approved protocol.
Patient-derived xenografts
PDXs were grown from nine tumors (two primary and seven metastatic) 
from six patients for two generations of passaging in nonobese 
diabetic/severe combined immunodeficient mice (NOD/SCID). This 
followed our recently published protocol (see also the Supplementary 
Methods) (31).
Multiregion whole-genome, exome, and targeted sequencing
The initially resected primary tumor region corresponding to the 
clinical specimen evaluated on standard pathology, all metastasis, 
and xenograft samples were sequenced for the discovery of somatic 
mutations. The initial primary region and all metastatic samples 
were sequenced using both whole-genome (~67× tumor mean 
coverage) and exome (~215× tumor mean coverage) sequencing. PDX 
samples were subjected to exome sequencing. All samples, including 
47 remaining multiregion primary samples, were then subjected to 
targeted validation sequencing (~251× tumor mean coverage) of 
152 cancer genes and >100,000 somatic mutations (detected in the 
discovery phase) covering all nonsilent coding SNVs, small insertions/
deletions (indels), and diploid heterozygous noncoding SNVs (Fig. 1, 
data S1, and Supplementary Methods). All sequencing data were 
deposited to the database of genotypes and phenotypes (dbGap) 
under the accession phs001722.
Reconstruction of clonal evolution
Heterozygous mutations validated in targeted sequencing were first 
clustered on the basis of their variant allele fraction using sciClone 
(32) to identify the founding clones and subclones that were sub-
sequently analyzed using ClonEvol (33) to infer clonal evolution 
models (Fig. 1). Further details regarding patients, PDXs, and materials 
and methods are provided in the Supplementary Materials.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/24/eaay9691/DC1
View/request a protocol for this paper from Bio-protocol.
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